May 16, 2022
Otsuka Pharmaceutical said on May 13 that it will terminate its global license pact with Akebia Therapeutics for the biotech’s renal anemia agent vadadustat, which was under codevelopment in the US, Europe, and other regions. The move follows the US...read more